Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply "precision medicine" to antimicrobial chemotherapy?
about
Clinical and laboratory considerations for the rapid detection of carbapenem-resistant Enterobacteriaceae.Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy against KPC-2-Producing Klebsiella pneumoniaeAssociation between the Presence of Aminoglycoside-Modifying Enzymes and In Vitro Activity of Gentamicin, Tobramycin, Amikacin, and Plazomicin against Klebsiella pneumoniae Carbapenemase- and Extended-Spectrum-β-Lactamase-Producing Enterobacter SpecEvaluating Polymyxin B-Based Combinations against Carbapenem-Resistant Escherichia coli in Time-Kill Studies and in a Hollow-Fiber Infection Model.Multidrug-resistant organisms in liver transplant: Mitigating risk and managing infections.Toward Precision Healthcare: Context and Mathematical Challengesβ-Lactamases: A Focus on Current Challenges.Ceftazidime-avibactam for the treatment of complicated intra-abdominal infections.Intravenous Fosfomycin for the treatment of hospitalized patients with serious infections.Evaluation of robenidine analog NCL195 as a novel broad-spectrum antibacterial agent.Population Pharmacokinetics of High Dose Continuous Infusion Meropenem and Considerations for the Use in the Treatment of Infections due to KPC-Producing Klebsiella pneumoniae.Double carbapenem as a rescue strategy for the treatment of severe carbapenemase-producing Klebsiella pneumoniae infections: a two-center, matched case-control study.What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?Evaluation of automated systems for aminoglycosides and fluoroquinolones susceptibility testing for Carbapenem-resistant Enterobacteriaceae.Structural modification of LPS in colistin-resistant, KPC-producing Klebsiella pneumoniae.Successful Treatment of Klebsiella pneumoniae Harboring a Klebsiella pneumoniae Carbapenemase Isolated from Lumbar Wound Infection and Blood in a Patient with Hardware Retention.A 17-Year Nationwide Study of Burkholderia cepacia Complex Bloodstream Infections Among Patients in the United States Veterans Health Administration.Molecular and epidemiological characterization of carbapenemase-producing Enterobacteriaceae in Norway, 2007 to 2014.Treatment of Hospital or Ventilator-Associated Pneumonia Due to Carbapenem-Resistant Enterobacteriaceae: Leveraging Molecular Resistance Testing and Combination Therapy to Improve Outcomes.Delivering precision antimicrobial therapy through closed-loop control systems.Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward 'molecularly targeted' therapy.Carbapenemase-Producing Organisms: A Global Scourge!Unusual Escherichia coli PBP 3 Insertion Sequence Identified from a Collection of Carbapenem-Resistant Enterobacteriaceae Tested In Vitro with a Combination of Ceftazidime-, Ceftaroline-, or Aztreonam-Avibactam.Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study.Risks of infection and mortality among patients colonized with KPC-producing Klebsiella pneumoniae: validation of scores and proposal for management.Carbapenemase-producing Enterobacteriaceae in Mexico: report of seven non-clonal cases in a pediatric hospital.Carbapenem-resistant Gram-negative pathogens in a German university medical center: Prevalence, clinical implications and the role of novel β-lactam/β-lactamase inhibitor combinations.Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.Meropenem/Vaborbactam: A Review in Complicated Urinary Tract InfectionsOverview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant
P2860
Q33816207-8973CF35-7D15-4535-A6A5-2864B03506FEQ37023175-B5F5B951-FB4D-425C-9264-3AA03D82A406Q37203715-AE04FD7D-7B9F-44EE-8107-D60EA2A3B1A3Q37538693-DDE649F2-D0DE-4944-A99D-FAB22EFEF13EQ38845084-B65DB0B7-324F-4975-8428-FDDD1C83BE46Q38854423-0DEA9B78-F1E5-4928-B7A0-1FDC347EBBCBQ38981257-8F050DA7-7600-4282-8AA9-8BF58C23A558Q38985065-98D6407E-665E-414C-BCF2-D9D7A9B0F627Q40049542-AB7AF878-6E65-4AED-B952-A5937A642A1FQ40066351-2ED69381-7EF0-42D6-B75E-9BB9781303DBQ40112541-57BD6D04-09F1-4343-BF7C-6073A12123E2Q40146757-F60D31BD-4731-4BDD-8905-68527ADA0047Q40550507-A347F10D-9944-47ED-A511-1260B8E3D640Q41215201-28786A85-DF64-4E0E-B7FC-411F810AE6F6Q41992943-24EBF7FD-BA3D-46E7-975A-34E997E1637FQ42718260-19C27840-B95E-4953-BDBB-9085FD7BDFF1Q45326027-330FE930-896A-40A1-AFD2-48E81980C0E3Q46034361-28B9F918-FDCC-4CFF-93FC-603AE1157A9AQ46264986-7304F935-A213-440B-AACA-47B74825A0D3Q47276911-3910C633-88F3-4CEC-B725-AF10017FC628Q47661746-9B2B1D5F-E41F-4CAC-AC57-B1A7C46E4781Q47699834-A79D1D7C-81CA-4ED0-96A5-28ECEF149F97Q48355486-B145773E-6431-4520-BAC1-DC9E3DF41DAEQ49633991-B9C8A14D-1ECF-43EC-9CD6-72503662BCCEQ50068803-162172FD-5E91-4471-B0AB-DA98AC5AE6D6Q52577425-6DD9E2D8-474A-469A-AF1C-CBB771F07B8AQ52591821-D3735EEA-2705-49B9-9E8A-65380393812AQ52695014-99111BA3-115A-47E5-B88A-2F3BE1DC3346Q58733616-AA90EB5A-1D50-45AE-BAA2-ADEE9466A733Q58746821-D81520DE-A745-45B3-AFDE-888AEEE2773F
P2860
Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply "precision medicine" to antimicrobial chemotherapy?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 January 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Treatment options for infectio ...... to antimicrobial chemotherapy?
@en
Treatment options for infectio ...... to antimicrobial chemotherapy?
@nl
type
label
Treatment options for infectio ...... to antimicrobial chemotherapy?
@en
Treatment options for infectio ...... to antimicrobial chemotherapy?
@nl
prefLabel
Treatment options for infectio ...... to antimicrobial chemotherapy?
@en
Treatment options for infectio ...... to antimicrobial chemotherapy?
@nl
P2093
P2860
P921
P1476
Treatment options for infectio ...... to antimicrobial chemotherapy?
@en
P2093
Brigid M Wilson
Federico Perez
Nadim G El Chakhtoura
P2860
P304
P356
10.1517/14656566.2016.1145658
P407
P577
2016-01-22T00:00:00Z